Medifactia Information

Medifactia AB is a Swedish medical device company that develops and manufactures Transit-Pellets®, a validated system for quantitative colonic transit time (CTT) assessment using radiopaque markers. A colonic transit test should do more than confirm that transit is slow. Transit-Pellets shows where the delay is — reporting total and segmental colonic transit across the full range, from rapid to slow, from a single abdominal X-ray on day seven. Built on the Transit-Pellets Method (originally Abrahamsson's) and decades of peer-reviewed research, and paired with a standardized reporting tool, it gives clinicians, radiologists, and care teams consistent, comparable results — moving motility care from symptom-based guessing to physiology-guided decisions. The test is non-invasive and completed at home over seven days. Transit-Pellets is available in two kits: a standard kit for adults, and Transit-Pellets Kids for children aged two and older. Transit-Pellets is CE marked (2016) and US FDA 510(k) cleared for adults (2019) and children ages 2+ (2023), manufactured under an ISO 13485 quality management system, and in clinical use across 14+ countries. Medifactia AB, headquartered in Stockholm, serves clinicians and distributors worldwide. Through its U.S. subsidiary, Medifactia Inc., the company is expanding access for clinicians and patients across the United States. Explore the method, the clinical evidence, and the reporting tool — with dedicated resources for clinicians, radiologists, procurement teams, patients, and parents — at medifactia.com and medifactiakids.com. Colon transit study · colonic transit marker test · radiopaque marker test